The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer

The Roles and Molecular Mechanism of Exosomal Circ-LRBA That Regulates miR-451/CRTC2 Signaling Axis in Colorectal Cancer Progression

Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Most of the patients with colorectal cancer were diagnosed in poor stage. Although 40% to 50% patients of colorectal cancer can be cured by surgery, but most patients have undergent metastasis or recurrence, and eventually death. In recent years, molecular targeted therapy has shown significant efficacy in specific patients. It was necessary to detect the corresponding molecular targets of tumors before selecting appropriate targeted drugs in clinic. The changing state of related gene molecules in colorectal cancer played a key role in drug selection, there were few effective targets so far. At present, metastasis and recurrence still be the most difficult problems in treatment. Therefore, investigators should deeply study the occurrence and development of colorectal cancer at the gene level and look for new biomarkers to predict the prognosis. Furthermore, the study can clarify the exact molecular mechanism of colorectal cancer. These will be important clinical significance for targeted therapy of colorectal cancer.

Study Overview

• Status: Recruiting
• Conditions: Colorectal Cancer
• Intervention / Treatment: Other: nothing

• Study Type: Observational
• Enrollment (Anticipated): 200

Contacts and Locations

• Study Contact: Name: Jingbo Chen, doctor; Phone Number: nothing 15053186972; Email: qychenjingbo@163.com

Study Locations

• China
  • Lixia
    • Jinan, Lixia, China, 250014
      • Recruiting
      • The First Affiliated Hospital Of Shandong First Medical University
      • Contact: Jingbo Chen, doctor; Phone Number: nothing 15053186972; Email: qychenjingbo@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

1

Description

Inclusion Criteria:

1.18-80 years old.

2.18.5 < BMI < 27.9.

3. The surgical methods are radical resection of rectal cancer, resection of right colon cancer, resection of left colon cancer and radical resection of sigmoid colon cancer.

Exclusion Criteria:

1. Those who refuse to collect samples.
2. Patients with severe dysfunction of coagulation, hepatorenal dysfunction or severe cardiopulmonary diseases.
3. Patients who has a history of neoadjuvant radiotherapy or chemotherapy.
4. Combining with distant multiple metastases of tumor

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
control group	Other: nothing; nothing
cancer group	Other: nothing; nothing

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
expressional quantity	Expression of CRTC2 in patient samples	Through study completion, an average of 2 year

Collaborators and Investigators

• Sponsor: Jingbo Chen

Study record dates

Study Major Dates

• Study Start (Anticipated): January 1, 2023
• Primary Completion (Anticipated): June 30, 2025
• Study Completion (Anticipated): December 31, 2026

Study Registration Dates

• First Submitted: October 9, 2022
• First Submitted That Met QC Criteria: October 11, 2022
• First Posted (Actual): October 13, 2022

Study Record Updates

• Last Update Posted (Actual): October 13, 2022
• Last Update Submitted That Met QC Criteria: October 11, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms
• Other Study ID Numbers: YXLL-KY-2022

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No